SUBSCRIBE
SUBSCRIBE
News   Business

Forest Laboratories, Inc. Revises Fiscal Year 2013 Earnings Guidance Primarily Due to Evolving Conditions in the Lexapro / escitalopram Market

June 11, 2012 | 
1 min read

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer, today announced revised FY 2013 earnings guidance.

Earnings
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
December 12, 2024
 · 
205 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie